Newsfeeds - Spark Newswire

1 minute read

Minerva Neurosciences Q4 EPS $(1.26) Misses $(0.92) Estimate, Cash, Cash Equivalents, And Restricted Cash Of $36.2M

Today, 10:09 PM

Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(1.26) per share which missed the analyst consensus estimate of $(0.92) by 36.96 percent. This is a 68.5 percent increase over losses of $(4.00) per share

NERV

6 minute read

Earnings

Earnings Scheduled For March 8, 2023

By Benzinga Insights

Today, 10:09 PM

Companies Reporting Before The Bell • Daktronics (NASDAQ:DAKT) is expected to report quarterly earnings at $0.00 per share on revenue of $164.68 million.

ABM

1 minute read

Minerva Neurosciences Has Been Granted Canadian Patent Number 3117855 Titled “Methods Of Use Of Cyclic Amide Derivatives To Treat Schizophrenia”

By Benzinga Newsdesk

Today, 10:09 PM

https://www.ic.gc.ca/opic-cipo/cpd/eng/patent/3117855/summary.html

EWC

2 minute read

EXCLUSIVE: The Benzinga Moneymaker Series, 5 Emerging Stocks For Investors To Watch

By Chris Katje

Today, 10:09 PM

Investors are on the hunt for undervalued, underfollowed and emerging stocks to spot opportunities. The rise of social media and retail traders gave way to countless methods to uncover new information. For some, this is overwhelming.

GRRR

2 minute read

Tesla, Amazon, Minerva, Kala Pharma, Gorilla Tech: Why These 5 Stocks Are Drawing Investors’ Attention Today

By Bhavik Nair

Today, 10:09 PM

Major Wall Street indices closed in the red on Wednesday as investors and traders lost optimism regarding any possible year-end rebound and braced themselves for the new year while lightening up on positions ahead of the end of the week.

AMZN

2 minute read

Nasdaq Down 100 Points; Kala Pharmaceuticals Shares Spike Higher

By Lisa Levin

Today, 10:09 PM

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 100 points on Wednesday.

GRRR

4 minute read

Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday’s Mid-Day Session

By Lisa Levin

Today, 10:09 PM

Gainers Kala Pharmaceuticals, Inc. (NASDAQ: KALA) shares gained 130.5% to $9.03 after the company announced FDA acceptance of a IND application for its KPI-012 for the treatment of persistent corneal epithelial defect.

$APE